Emiliano Spagnolo

CellPly SRL develops and markets customized diagnostic tools for cancer treatment. The firm specializes in the design and marketing of solutions for defining the efficacy of immunotherapies and chemotherapies on cancer and immune cells. It offers a platform that analyzes ex-vivo samples and rare cells immediately after obtaining them from patients and preserving microenvironment conditions to readily provide information about tumor cell sensitivity to drugs and in-vivo status of single immune cells located close to tumor cells. The firm focuses on helping oncologists selecting the best treatment options, scientists studying cell response to therapy, and pharmaceutical companies increasing drug efficacy and rescuing drugs with limited efficacy through patient stratification. The company was founded by Massimo Bocchi and Roberto Guerrieri in 2013 and is headquartered in Bologna, Italy.

CellPly SRL develops and markets customized diagnostic tools for cancer treatment. The firm specializes in the design and marketing of solutions for defining the efficacy of immunotherapies and chemotherapies on cancer and immune cells. It offers a platform that analyzes ex-vivo samples and rare cells immediately after obtaining them from patients and preserving microenvironment conditions to readily provide information about tumor cell sensitivity to drugs and in-vivo status of single immune cells located close to tumor cells. The firm focuses on helping oncologists selecting the best treatment options, scientists studying cell response to therapy, and pharmaceutical companies increasing drug efficacy and rescuing drugs with limited efficacy through patient stratification. The company was founded by Massimo Bocchi and Roberto Guerrieri in 2013 and is headquartered in Bologna, Italy.

CellPly SRL develops and markets customized diagnostic tools for cancer treatment. The firm specializes in the design and marketing of solutions for defining the efficacy of immunotherapies and chemotherapies on cancer and immune cells. It offers a platform that analyzes ex-vivo samples and rare cells immediately after obtaining them from patients and preserving microenvironment conditions to readily provide information about tumor cell sensitivity to drugs and in-vivo status of single immune cells located close to tumor cells. The firm focuses on helping oncologists selecting the best treatment options, scientists studying cell response to therapy, and pharmaceutical companies increasing drug efficacy and rescuing drugs with limited efficacy through patient stratification. The company was founded by Massimo Bocchi and Roberto Guerrieri in 2013 and is headquartered in Bologna, Italy.